This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.
April 2020
*Use the arrows at the bottom of the dashboard to move through the pages *To clear filters use eraser icon alongside the name of the filter * For multiple selection in the drop downs, press and hold CTRL We cannot guarantee the completeness of this list at the time of viewing, but are working actively …
May 2020
NIHR Innovation Observatory Soft Intelligence Squad
About The NIHR Innovation Observatory’s Soft Intelligence Squad (NIHRIO SIS) are monitoring, tracking, and analysing ‘soft intelligence’ to explore health impacts. Mobilised in March 2020, the group are using novel text mining and machine learning techniques, involving sentiment detection, analysis, and classification, to help extract and synthesise meaningful insights from the ‘public voice’. Led and …
April 2020
*Use the arrows at the bottom of the dashboard to move through the pages *To clear filters use eraser icon alongside the name of the filter *For multiple selection in the drop downs, press and hold CTRL *To navigate in the map, click on the country (continue to hover to see numbers of trials; graph …
Drugs
July 2021
Afamitresgene autoleucel for advanced synovial sarcoma or myxoid/round cell liposarcoma
Afamitresgene autoleucel is in clinical development for the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) in patients who have previously had chemotherapy. Both synovial sarcoma and MRCLS are two different types of soft tissue sarcomas (STS), a rare form of cancer that develops in the tissues that connect, support and surround other …
Drugs
July 2021
The combination of pembrolizumab, lenvatinib, platinum chemotherapy, and pemetrexed is in clinical development for the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and at the metastatic stage (stage IV), the disease has already spread from the lungs to other sites. Most patients …
Drugs
July 2021
Dronabinol for muscle spasticity caused by multiple sclerosis
Dronabinol is in clinical development for the treatment of spasticity caused by multiple sclerosis (MS). MS is a long-term condition that affects the brain and spinal cord, causing a range of symptoms including spasticity. Spasticity is when the muscles become stiff and resistant to movement, which can be extremely painful. There are currently limited treatment …
Drugs
July 2021
Leronlimab in addition to antiretroviral therapy for treatment experienced adult HIV-1 patients
Leronablim is in clinical development to treat experienced adult HIV-1 patients infected with C-C chemokine receptor type 5 (CCR5)-tropic virus. Antiretroviral medicines are used to treat HIV. However, poor adherence and the subsequent development of drug resistance is one reason why HIV treatment can fail and therefore requires more treatment options. Leronlimab is an antibody …
Drugs
July 2021
Nivolumab in combination with ipilimumab is under development for the treatment of advanced gastric or gastroesophageal junction cancer. Gastric cancer is a malignant tumour originating in the cells of the stomach. Advanced gastric cancer begins in the stomach and spread into the tissues around the stomach, either as locally advanced disease, or it can metastasise …
Drugs
July 2021
Risankiziumab for moderate to severe crohn’s disease
Risankizumab is in development as a treatment option for moderate to severe Crohn’s disease (CD). CD is a type of inflammatory bowel disease which can affect any part of the digestive system. CD causes inflammation and ulceration, which affects food digestion, nutrient absorption, and waste elimination. Symptoms include abdominal pain, diarrhoea, weight loss and fatigue. …
Drugs
July 2021
Daprodustat for anaemia associated with chronic kidney disease
Daprodustat is in clinical development for people with anaemia associated with chronic kidney disease (CKD). Anaemia is the term used to describe a decrease in normal levels of red blood cells and is assessed by the level of haemoglobin, the protein that transports oxygen throughout the body. Anaemia commonly occurs in patients with kidney dysfunction …